Biotherapeutics Cell Line Development Market: Worldwide Market Shares, Strategies, and Forecasts 2015 to 2022

Some of the key players operating in the global biotherapeutics cell line development market are Becton, Dickinson and Company; Beckman Coulter, Inc.; Boehringer lngelheim Group; Catalent, Inc.; and Lonza Group Ltd. Among them, Becton Dickinson offers products related to biotherapeutics cell line development under the BD Biosciences segment. The company’s customer base is comprised of clinics, hospitals, pharmaceutical and biotechnology companies, research, industrial, and food microbiology labs. The company’s main thrust has been on developing innovative products.
Beckman Coulter, Inc., another key player in the global market for biotherapeutics cell line development, has furthered its market position with strategic acquisitions and an expanding product portfolio. Germany-based Boehringer Ingelheim has resorted to strategic partnerships to enhance its market share. It has also expanded in developing economies such as China to improve its market standing.
This 104 page report gives readers a comprehensive overview of the Biotherapeutics Cell Line Development Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html
Registering a CAGR of 7.50% from 2015 to 2022, the global biotherapeutics cell line development market is anticipated to reach a value of US$100 mn by 2022.
Quick Uptake of ClonePix and FACS Makes Transfection the Dominant Segment
Based on the process, the global biotherapeutics cell line development market can be bifurcated into transfection and single cell cloning. Among the two, the single cell cloning dominates the market with a lion’s share in the revenue because of quick adoption of instruments such as ClonePix and FACS. ClonePix has been more widely adopted so far on account of a greater demand for automated systems over the traditional limited dilution method which soaks up a lot of time.
The market for transfection comprising of consumables is expected to outpace that of single cell cloning in terms of growth rate in the future. The revenue in this section was US$57.63 mn in 2015.
Geography-wise, North America has been a market leader so far and going forward, it is predicted to maintain its leading share. In 2015 its revenue was worth US$25.20 mn. Europe follows in the second position. Both the continents have been market leaders on account of their burgeoning geriatric population and rampant occurrence of different maladies. Rise in demand for protein therapeutics such as monoclonal antibodies is also predicted to generate demand for mammalian cell line development for biotherapeutics. Asia Pacific is poised for maximum growth on account of the increasing outsourcing of biotherapeutics manufacture to third parties in developing countries in the region, which is cost effective for companies.
Growing Elderly Population Susceptible to Different Maladies Driving Growth
As far as market drivers are concerned, a rising elderly population is at the forefront of bringing about growth. Highly susceptible to chronic, degenerative, and autoimmune diseases such as diabetes, cancer, and multiple sclerosis, their medical requirements is majorly contributing to the biotherapeutics and consequently cell line development market. Another factor driving the market is the demand for monoclonal antibodies (mAb). “Monoclonal antibodies are used in a wide range of therapeutic applications and to treat various diseases such as cancer, multiple sclerosis, asthma and rheumatoid arthritis. Demand for monoclonal antibodies is driven by the understanding of disease (target) and treatment (drug) at a molecular level,” elaborates the analyst of the TMR report.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Biotherapeutics Cell Line Development Market during 2015 - 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272
Countering the growth of the market is the dearth of skilled professionals to meet growing requirement for fast moving and technologically advanced pharmaceutical and biotechnology products. This in term acts as a deterrent for establishing off-shore research and development facilities. Another market deterrent is stringent regulations. “Several compliance guidelines with international standards are in place such as International Standards Organization (ISO) quality concepts to ensure safe biopharmaceuticals and the World Health Organization (WHO),” informs the lead analyst of the report.
This review is based on the findings of a TMR report titled “Biotherapeutics Cell Line Development Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2022.” 

Biotherapeutics Cell Line Development Market: Current Market and Future Players by Transparecy Market Research

With the increasing number of recombinant protein therapeutics gaining approval by the U.S. Food and Drug Administration (FDA) annually, there is an increase in the demand of cell lines for production of these biotherapeutics. From 2006 to 2011 an average of 15 novel recombinant protein therapeutics and in 2014, 11 novel recombinant protein therapeutics have been approved by US FDA. About forty-seven monoclonal antibody products have been approved in the U.S., Europe and other global markets, of which over 60% were produced in mammalian cell culture. Moreover, the rise in the geriatric population coupled with prevalence of diseases is one of the major factors driving the demand for cell line development for biotherapeutics. The increasing demand for monoclonal antibodies across the globe boosts the market growth. In addition, the increasing number of initiatives taken by the government of various countries by funding the life science research and development is expected to propel this market in coming years.
This 104 page report gives readers a comprehensive overview of the Biotherapeutics Cell Line Development Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html
The global biotherapeutics cell line development market is segmented by process, by cell line development option and by geography. The market by process segment has been sub-segmented as transfection and single cell cloning. The single cell cloning market is further sub-segmented by method into manual limited dilution cloning, FACS, ClonePix and Others. The market by CLD option is segmented as In-house, outsource, hybrid and do-it-yourself. The ClonePix accounted for the largest market share of 37.4% in 2014. Geographically, the market has been studied and estimated for five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes market attractiveness analysis, by geography, to provide a thorough analysis of the overall competitive scenario in the global biotherapeutics cell line development market. The market overview section of the report also includes the qualitative and quantitative analysis of the competitive landscape.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Biotherapeutics Cell Line Development Market during 2015 - 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272
Market share analysis for FACS market is also provided in the market overview section of the report for 2014 in terms of value (%). The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the biotherapeutics cell line development market across the world. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Major players in this market are Becton Dickinson & Company (U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation) (Japan), ProBioGen AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC. (U.S.), Sony Biotechnology Inc. (U.S.), and Thermo Fisher Scientific Inc. (U.S.). 

Biotherapeutics Cell Line Development Market: Industry Overview and Key Factors

A high degree of consolidation is the defining feature of the competitive landscape of the global biotherapeutics cell line development market, finds Transparency Market Research. Becton Dickinson and Co. and Beckman Coulter, the top two companies operating in the biotherapeutics cell line development market, accounted for 85% of the overall market in 2015.

This consolidation has led to reduced market shares for other players and has also abated the possibility of new entrants, thereby offering prominent opportunities for business expansion existing leaders. Over the coming years, these players will need to focus on advancements in technologies to gain a competitive edge over each other.

Unmet Medical Needs in Emerging Economies to Present Lucrative Opportunities for Biotherapeutics Cell Line Development

This 104 page report gives readers a comprehensive overview of the Biotherapeutics Cell Line Development Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html

The increasing prevalence of chronic diseases, stimulated by the rapid growth of the global geriatric population, has created favorable conditions for the progression of biotherapeutics. Currently, the increasing percentage of elderly individuals in the world’s population is a significant trend, which is likely to intensify over the years to come. This rise in geriatric population is impelling the incidence of chronic, degenerative, and autoimmune diseases such as diabetes, cancer, and multiple sclerosis. Biotherapeutics, supported by its high efficiency, is grabbing substantial attention from patients as well as medical professionals for the treatment of these diseases, leading to a significant thrust to the development of biotherapeutics cell line across the world.

Looking forward, emerging economies in Asia Pacific, Latin America, and Africa, laden with unmet medical needs, will provide lucrative opportunities for biotherapeutics cell line development over the next few years. Apart from this, the growing demand for monoclonal antibodies is also projected to stimulate development activities for these cell lines in the near future.

Stringent Regulations Could Delay Product Development, Hamper Market Growth

Although the market for biotherapeutics cell line development looks thriving at present, the stringent norms and policies that regulate cell culture procedures in the production of biotherapeutics create severe issues for market participants.

As the development of stable cell line producing biologics needs to follow standard operating procedures and compliance, and requires to monitor product quality by performing tests in line with SOPs and regulations, existing players face delay in product development. These regulations also restrict the entry of new players in this market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Biotherapeutics Cell Line Development Market during 2015 - 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272

Single Cell Cloning to Remain Most Preferred Process for Cell Line Development

The global market for biotherapeutics cell line development is estimated to expand at a steady CAGR of 7.50% during the period from 2015 to 2022, with the opportunity rising from US$56.03 mn in 2014 to US$99.8 mn by the end of the forecast period.

North America has been leading this market since the last few years and is projected to remain the key revenue contributor in the near future. The region is likely to witness a rise in its market opportunity from US$23.5 mn in 2014 to US$41 mn by 2022. However, Asia Pacific is anticipated to report the fastest CAGR of 9.40% during the forecast period.

Single cell cloning was the main cell line development process followed in 2014. Analysts expect it to continue to lead with a majority share throughout the forecast period. Outsourcing will emerge as the most preferred cell line development option for biotherapeutics over the forthcoming years, states TMR.

The information presented in this review is based on the findings of a report by Transparency Market Research titled "Biotherapeutics Cell Line Development Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2022."

Key Takeaways

• Top three players accounted for 85% of the overall market in 2015
• Stringent norms could create obstacles for market players
• Asia Pacific is anticipated to grow at the fastest rate during the forecast period

Biotherapeutics Cell Line Development Market Segment Forecasts up to 2022, Research Reports

A high degree of consolidation is the defining feature of the competitive landscape of the global biotherapeutics cell line development market, finds Transparency Market Research. Becton Dickinson and Co. and Beckman Coulter, the top two companies operating in the biotherapeutics cell line development market, accounted for 85% of the overall market in 2015.

This consolidation has led to reduced market shares for other players and has also abated the possibility of new entrants, thereby offering prominent opportunities for business expansion existing leaders. Over the coming years, these players will need to focus on advancements in technologies to gain a competitive edge over each other.

Unmet Medical Needs in Emerging Economies to Present Lucrative Opportunities for Biotherapeutics Cell Line Development

This 104 page report gives readers a comprehensive overview of the Biotherapeutics Cell Line Development Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html

The increasing prevalence of chronic diseases, stimulated by the rapid growth of the global geriatric population, has created favorable conditions for the progression of biotherapeutics. Currently, the increasing percentage of elderly individuals in the world’s population is a significant trend, which is likely to intensify over the years to come. This rise in geriatric population is impelling the incidence of chronic, degenerative, and autoimmune diseases such as diabetes, cancer, and multiple sclerosis. Biotherapeutics, supported by its high efficiency, is grabbing substantial attention from patients as well as medical professionals for the treatment of these diseases, leading to a significant thrust to the development of biotherapeutics cell line across the world.

Looking forward, emerging economies in Asia Pacific, Latin America, and Africa, laden with  unmet medical needs, will provide lucrative opportunities for biotherapeutics cell line development over the next few years. Apart from this, the growing demand for monoclonal antibodies is also projected to stimulate development activities for these cell lines in the near future.

Stringent Regulations Could Delay Product Development, Hamper Market Growth

Although the market for biotherapeutics cell line development looks thriving at present, the stringent norms and policies that regulate cell culture procedures in the production of biotherapeutics create severe issues for market participants.

As the development of stable cell line producing biologics needs to follow standard operating procedures and compliance, and requires to monitor product quality by performing tests in line with SOPs and regulations, existing players face delay in product development. These regulations also restrict the entry of new players in this market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Biotherapeutics Cell Line Development Market during 2015 - 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272

Single Cell Cloning to Remain Most Preferred Process for Cell Line Development

The global market for biotherapeutics cell line development is estimated to expand at a steady CAGR of 7.50% during the period from 2015 to 2022, with the opportunity rising from US$56.03 mn in 2014 to US$99.8 mn by the end of the forecast period.

North America has been leading this market since the last few years and is projected to remain the key revenue contributor in the near future. The region is likely to witness a rise in its market opportunity from US$23.5 mn in 2014 to US$41 mn by 2022. However, Asia Pacific is anticipated to report the fastest CAGR of 9.40% during the forecast period.

Single cell cloning was the main cell line development process followed in 2014. Analysts expect it to continue to lead with a majority share throughout the forecast period. Outsourcing will emerge as the most preferred cell line development option for biotherapeutics over the forthcoming years, states TMR.

The information presented in this review is based on the findings of a report by Transparency Market Research titled "Biotherapeutics Cell Line Development Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2022."

Key Takeaways

• Top three players accounted for 85% of the overall market in 2015
• Stringent norms could create obstacles for market players
• Asia Pacific is anticipated to grow at the fastest rate during the forecast period

Continued Research Makes Biotherapeutics Cell Line Development Market a Highly Attractive Space

Over the past few years, the demand for biotherapeutics has witnessed a significant rise, thanks to the increasing prevalence of chronic diseases such as diabetes, rheumatoid arthritis, cancer, and multiple sclerosis. This growth in the demand for biotherapeutics, together with the imminent launch of several biopharmaceutical drugs, has created a substantial demand for cell line development.

On the other hand, the strict rules and policies, regulating cell culture procedures in the production of biotherapeutics are creating difficulties for participants in their business expansion. However, unmet medical needs in emerging economies of Asia Pacific, Latin America, and Africa, is expected to provide lucrative opportunities for market players over the next few years.

The global market for is estimated to with the opportunity in biotherapeutics cell line development will rise from US$56 mn in 2014 to nearly US$100 mn by 2022, rising at a CAGR of 7.50% between 2015 and 2022.

Asia Pacific to Provide Potential Opportunities for Cell Line Development in Biotherapeutics

North America has acquired the leading position in the worldwide market for biotherapeutics cell line development. In 2014, the opportunity in this region stood at US$23.5 mn, which is likely to increase to US$41 mn by the end of 2022. The presence of a large pool of leading biopharmaceutical companies has stimulated the biotherapeutics cell line development activities in this region, leading to remarkable growth in the market. The increasing base of geriatric population in this region is also presenting huge opportunities for the development of cell lines in biotherapeutics.

Europe, which emerged second in this market in 2014, is expected to report steady growth in the near future, thanks to the rising demand for biotherapeutics. The future of cell line development in biotherapeutics, however, lies in Asia Pacific, which stood at third position in 2014. The potential that this region holds can be understood by the fact that Asia Pacific is expected to register the fastest CAGR of 9.40% during the forecast period. The unmet medical needs and the increasing investments by major pharma companies is projected to amplify the development of biotherapeutics cell line in this region.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272

Transfection and Selection to Report Higher Growth Rate in Near Future

Single cell cloning and transfection and selection are the two main processes for biotherapeutics cell line development. Single cell cloning led the market with a share of 96% in 2014. The growing adoption of instruments such as FACS and ClonePix has added significantly to the growth of single cell cloning in the recent times.

Although the single cell cloning segment is likely to remain leading throughout the forecast period; the transfection and selection segment with register a higher growth rate in the coming years, owing to the increase in the demand for monoclonal antibodies.

The top two players in the global biotherapeutics cell line development market are Becton Dickinson and Co. and Beckman Coulter. Boehringer Ingelheim Pharma GmbH & Co KG., CMC Biologics, Catalent Inc., Lonza Group Ltd., ProBioGen AG, Partec, SAFC, Sony Biotechnology Inc., Selexis SA, and Thermo Fisher Scientific Inc. are some of the other prominent market participants.